← back to search

Cheryl Selinsky

Parker Institute for Cancer Immunotherapy · US
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Immunotherapy and Immune Responses, and Cancer Genomics and Diagnostics.
h-index
9
citations
1,074
works
15
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
The Lancet Oncology 2020cited by 298position: middledoi
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
Cancer Research 2019cited by 65position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zev A. Wainberg · UCLA Medical Center1 papers (2019–2019)Ute Dugan · Parker Institute for Cancer Immunotherapy1 papers (2019–2019)Erica L. Carpenter · Abramson Cancer Center1 papers (2019–2019)George A. Fisher · Stanford Medicine1 papers (2019–2019)Robert H. Vonderheide · Cancer Research Institute of the Slovak Academy of Sciences1 papers (2019–2019)Mark H. O’Hara · UPMC Hillman Cancer Center1 papers (2019–2019)Jaclyn P. Lyman · Kettering University1 papers (2019–2019)Christopher R. Cabanski · Parker Institute for Cancer Immunotherapy1 papers (2019–2019)Pier Federico Gherardini · University of Rome Tor Vergata1 papers (2019–2019)Rosemarie Mick · Parker Institute for Cancer Immunotherapy1 papers (2019–2019)Vanessa M. Hubbard-Lucey · Cancer Research Institute1 papers (2019–2019)Theresa LaVallee · Coherus BioSciences (United States)1 papers (2019–2019)Andrew H. Ko · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2019–2019)Eileen M. O’Reilly · Erasmus MC Cancer Institute1 papers (2019–2019)Osama E. Rahma · AstraZeneca (South Korea)1 papers (2019–2019)Lacey J. Kitch · Parker Institute for Cancer Immunotherapy1 papers (2019–2019)— · 1 papers (2019–2019)Ovid Trifan · Apexigen (United States)1 papers (2019–2019)Gauri R. Varadhachary · The University of Texas MD Anderson Cancer Center1 papers (2019–2019)